Research programme: biologics - Huabo Biopharm
Alternative Names: HB-005; HB-005db; HB-008; HB-016; HB-018Latest Information Update: 28 Feb 2022
At a glance
- Originator Huabo Biopharm
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Lymphoma; Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Breast-cancer in China (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Solid-tumours in China (Parenteral)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Lymphoma in China (Intraperitoneal)